Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain

Matsuoka, H; Clark, K; Fazekas, B; Oyamada, S; Brown, L; Ishiki, H; Matsuda, Y; Hasuo, H; Ariyoshi, K; Lee, J; Le, BH; Fujiwara, N; Miyaji, T; Agar, MR; Yamaguchi, T; Satomi, E; Iwase, S; Phillips, J; Koyama, A; Currow, DC

Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain

Matsuoka, H Clark, K Fazekas, B Oyamada, S Brown, L Ishiki, H Matsuda, Y Hasuo, H Ariyoshi, K Lee, J Le, BH Fujiwara, N Miyaji, T Agar, MR Yamaguchi, T Satomi, E Iwase, S Phillips, J Koyama, A Currow, DC

Permalink

Publisher:: LIPPINCOTT WILLIAMS & WILKINS
Publication Type:: Conference Proceeding
Citation:: JOURNAL OF CLINICAL ONCOLOGY, 2023, 41, (16)
Issue Date:: 2023-06-01

Closed Access

	Filename	Description	Size
	matsuoka-et-al-2023-phase-iii-international-multicentre-double-blind-dose-increment-parallel-arm-randomised-controlled.pdf	Published version	35.02 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Matsuoka, H
dc.contributor.author	Clark, K
dc.contributor.author	Fazekas, B
dc.contributor.author	Oyamada, S
dc.contributor.author	Brown, L
dc.contributor.author	Ishiki, H
dc.contributor.author	Matsuda, Y
dc.contributor.author	Hasuo, H
dc.contributor.author	Ariyoshi, K
dc.contributor.author	Lee, J
dc.contributor.author	Le, BH
dc.contributor.author	Fujiwara, N
dc.contributor.author	Miyaji, T
dc.contributor.author	Agar, MR
dc.contributor.author	Yamaguchi, T
dc.contributor.author	Satomi, E
dc.contributor.author	Iwase, S
dc.contributor.author	Phillips, J
dc.contributor.author	Koyama, A
dc.contributor.author	Currow, DC
dc.date	2023-06-02
dc.date.accessioned	2024-02-05T04:57:43Z
dc.date.available	2024-02-05T04:57:43Z
dc.date.issued	2023-06-01
dc.identifier.citation	JOURNAL OF CLINICAL ONCOLOGY, 2023, 41, (16)
dc.identifier.issn	0732-183X
dc.identifier.issn	1527-7755
dc.identifier.uri	http://hdl.handle.net/10453/175294
dc.language	en
dc.publisher	LIPPINCOTT WILLIAMS & WILKINS
dc.relation	http://purl.org/au-research/grants/nhmrc/APP1188023
dc.relation.ispartof	JOURNAL OF CLINICAL ONCOLOGY
dc.relation.ispartof	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.classification	3211 Oncology and carcinogenesis
dc.title	Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain
dc.type	Conference Proceeding
utslib.citation.volume	41
utslib.location.activity	IL, Chicago
utslib.for	1103 Clinical Sciences
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
dc.date.updated	2024-02-05T04:57:42Z
pubs.finish-date	2023-06-06
pubs.issue	16
pubs.publication-status	Published
pubs.start-date	2023-06-02
pubs.volume	41
utslib.citation.issue	16

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/175294